Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell receptor (TCR) recognizing Hemagglutinin (HA)-derived peptides is a specialized protein complex on T lymphocytes essential for identifying influenza virus infections. It specifically binds to HA peptide fragments, such as the immunodominant HA 306-318 sequence, when they are presented by Major Histocompatibility Complex (MHC) molecules, particularly HLA-DR4 (Hennecke & Wiley, 2002, Nature). This binding event triggers the CD3 signaling complex, leading to T-cell activation, proliferation, and the secretion of effector cytokines like interferon-gamma (Vogt et al., 1994, J. Immunol.). In the context of therapeutic development, this TCR serves as a primary model for TCR-engineered T-cell (TCR-T) therapies and the evaluation of universal influenza vaccines. The interaction is highly specific, yet research into its cross-reactivity is vital to prevent autoimmune responses where the TCR might mistakenly recognize self-peptides (Borbulevych et al., 2009, J. Immunol.). Drugs that modulate this target include general immunosuppressants that inhibit TCR signaling pathways, such as calcineurin inhibitors. Furthermore, the structural analysis of this TCR-pMHC complex has provided fundamental insights into the biophysics of immune recognition. Monitoring the presence and activity of T cells bearing this receptor is often used as a biomarker for vaccine efficacy and natural immunity to influenza.
The TCR complex recognizes specific HA peptides presented by MHC molecules, initiating a signaling cascade through the CD3 complex and downstream kinases like ZAP-70 to drive T-cell effector functions.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognizing Hemagglutinin-derived peptides (TCR-HA) (TCR-HA).